Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

Gerald HJ Mickisch1, Björn Schwander2, Bernard Escudier3, Joaquim Bellmunt4, José P Maroto5, Camillo Porta6, Stefan Walzer7, Uwe Siebert8,91Department of Urology, Center of Operative Urology Bremen, Bremen, Germany; 2Department of Outcomes Research, AiM GmbH Assessment-in...

Full description

Bibliographic Details
Main Authors: Gerald HJ Mickisch, Björn Schwander, Bernard Escudier, et al
Format: Article
Language:English
Published: Dove Medical Press 2011-01-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/indirect-treatment-comparison-of-bevacizumab--interferon-alpha-2a-vs-t-a6126

Internet

http://www.dovepress.com/indirect-treatment-comparison-of-bevacizumab--interferon-alpha-2a-vs-t-a6126

Similar Items